Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel for Sporadic ALS
NCT03019419Phase 2Completed
- Sponsor
- Tokyo Medical University
- Start
- Apr 2017
- Primary completion
- Dec 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of perampanel in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Tokyo Medical University. Primary endpoint: Change in ALS Functional Rating Scale-Revised at 48 weeks. Started Apr 2017; status: completed.
02
Drugs
perampanel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03019419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019419.